Boston Scientific Corporation
BSX · NYSE
- $42.98
- $65.29B
- Open
- —
- —
- $43.85 - $45.15
- $42.20 - $105.65
- —
- —
- 20.52M
About Boston Scientific Corporation
Boston Scientific is a healthcare medical-device company that earns revenue by selling products used in clinical procedures. The supplied evidence specifically identifies the WATCHMAN left-atrial-appendage product and electrophysiology, or EP, products as important businesses, while its reported materials do not quantify their individual contributions or provide a complete segment breakdown. Customers are healthcare providers and clinicians using these devices in patient treatment. Boston Scientific reported $20.1 billion of fiscal 2025 revenue and $2.9 billion of net income, compared with $16.7 billion and $1.8 billion, respectively, in fiscal 2024.
Notable Price Movement
- Aug 3-7$49.315.52%
Boston Scientific rose $3.03, or 6.58%, from $46.06 to $49.09 over the reported week. The advance began before the week, with the stock moving from $46.00 on July 30 to $46.73 on July 31, then extending gains to $48.43 on August 3 and $49.09 on August 4. The main company-specific catalyst was second-quarter performance: revenue grew at the high end of guidance and adjusted earnings per share exceeded expectations. Investors also responded to management’s cost-savings initiatives and future product catalysts, while an August 4 report highlighted a recent insider purchase by Director Edwar. The rally persisted despite management lowering its full-year outlook because of WATCHMAN and electrophysiology pressure.
